Recombinant technology specialist Sino Biological Inc (SZ:301047) announced on Tuesday the launch of its XPressMAX Cell-Free Protein Synthesis Kit (Cat#: CFKIT02), designed to supercharge artificial intelligence (AI)-driven high-throughput screening pipelines for antibody drug discovery.

The novel kit uses advanced cell-free protein synthesis technology to allow rapid in vitro production of target proteins and antibodies, eliminating the constraints of traditional cell-based expression systems.

According to Sino Biological, by seamlessly integrating with AI-powered screening platforms, the kit helps researchers accelerate the identification and optimisation of antibody candidates, reducing both development timelines and costs.

Dr. Rob Burgess, chief business officer at Sino Biological US Inc, said: "Our XPressMAX is a significant advancement in research tools and reagents for next-generation therapeutic discovery. By combining rapid, reliable protein expression with intelligent screening, we are helping our partners compress antibody discovery timelines without compromising quality."